%PDF-1.4
%
99 0 obj
<>
endobj
96 0 obj
<>
endobj
189 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-02-06T10:01:10Z
2024-03-28T17:59:05-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T17:59:05-07:00
application/pdf
Heather
2003-818.marchsupl.69
uuid:174170df-1dd2-11b2-0a00-370927bd3700
uuid:174170e2-1dd2-11b2-0a00-5b0000000000
endstream
endobj
85 0 obj
<>
endobj
86 0 obj
<>
endobj
100 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 65 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 67 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 69 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 71 0 R/Type/Page>>
endobj
25 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 73 0 R/Type/Page>>
endobj
33 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 75 0 R/Type/Page>>
endobj
41 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 77 0 R/Type/Page>>
endobj
49 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 79 0 R/Type/Page>>
endobj
220 0 obj
[224 0 R]
endobj
221 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
[(van de Putte LB. Ef)17.7 (fects of hydroxychloroquine and sulphasalazine)]TJ
0 -1.25 TD
(on progression of joint damage in rheumatoid arthritis. Lancet)Tj
0 Tc 0 Tw T*
(1989;1:1036-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875.1 (V)110.8 (an der Heijde D. How to read radiographs according to the)]TJ
2.175 -1.25 Td
(Sharp/van der Heijde method. J Rheumatol 1999;26:743-5.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Swinkels HL, Laan RF)79.7 (, van\325)17.7 (t Hof MA, van der Heijde DM, de)]TJ
2.175 -1.25 Td
[(V)59.8 (ries N, van Riel PL. Modified Sharp method: factors influencing)]TJ
T*
[(reproducibility and variability)64.8 (. Semin )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2001;31:176-90.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Pincus )17.7 (T)74 (, Larsen )54.8 (A, Brooks RH, Kaye J, Nance P)110.7 (, Callahan LF)79.7 (.)]TJ
2.175 -1.25 Td
(Comparison of 3 quantitative measures of hand radiographs in)Tj
T*
(patients with rheumatoid arthritis: Steinbrocker stage, Kaye )Tj
T*
(modified sharp score, and Larsen score. J Rheumatol)Tj
0 Tc 0 Tw T*
(1997;24:2106-3.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (V)110.8 (an der Heijde DMFM, van Riel PLCM, van de Putte LBA.)]TJ
2.175 -1.25 Td
[(Sensitivity of a Dutch Health )54.8 (Assessment Questionnaire in a trial)]TJ
T*
(comparing hydroxychloroquine vs sulphasalazine. Scand )Tj
T*
(J Rheumatol 1990;19:107-12.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Zandbelt M, )17.7 (W)79.9 (elsing PMJ, van Gestel )54.8 (AM, van Riel PLCM. Health)]TJ
2.175 -1.25 Td
(Assessment Questionnaire modifications: is standardisation)Tj
0 Tc T*
[(needed? )54.9 (Ann Rheum Dis 2001;60:841-5.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (van der Heijde DMFM, van Riel PLCM, Nuver)19.7 (-Zwart IH, van de)]TJ
2.175 -1.25 Td
(Putte LBA. Sulphazalazine versus hydroxychloroquine in )Tj
T*
(rheumatoid arthritis: 3-year follow-up [letter]. Lancet 1990;3:539.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual)]TJ
2.175 -1.25 Td
(radiographic assessments of hands and feet in a three-year )Tj
T*
(prospective followup of patients with early rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1992;35:26-34.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte)]TJ
2.175 -1.25 Td
(LB. Radiographic progression on radiographs of hands and feet)Tj
T*
(during the first 3 years of rheumatoid arthritis measured according)Tj
T*
[(to Sharp\325)54.8 (s method \(van der Heijde modification\). J Rheumatol)]TJ
0 Tc 0 Tw T*
(1995;22:1792-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (Albers JM, Kuper HH, van Riel PL, et al. Socio-economic )]TJ
2.175 -1.25 Td
(consequences of rheumatoid arthritis in the first years of the)Tj
T*
(disease. Rheumatology Oxford;1999;38:423-30.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (Kroot EJ, van Leeuwen MA, van Rijswijk MH, et al. No increased)]TJ
2.175 -1.25 Td
(mortality in patients with rheumatoid arthritis: up to 10 years of)Tj
T*
[(follow up from disease onset. )54.8 (Ann Rheum Dis 2000;59:954-8.)]TJ
30.825 47.5 Td
[(24.)-875.1 (W)39.8 (ijnands MJ, van\325)17.7 (t Hof MA, van de Putte LB, van Riel PL.)]TJ
2.175 -1.25 Td
[(Rheumatoid arthritis: a risk factor for sulphasalazine toxicity? )54.8 (A)]TJ
T*
(meta-analysis. Br J Rheumatol 1993;32:313-8.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Kroot EJ, de Jong BA, van Leeuwen MA, et al. )17.7 (The prognostic)]TJ
2.175 -1.25 Td
(value of anti-cyclic citrullinated peptide antibody in patients with)Tj
T*
[(recent-onset rheumatoid arthritis. )54.8 (Arthritis Rheum 2000;43:1831-5.)]TJ
-2.175 -1.25 Td
[(26.)-875.1 (Evers )54.8 (A)79.8 (W)91.8 (, Kraaimaat FW)91.7 (, van Riel PL, Bijlsma JW)91.7 (. Cognitive,)]TJ
2.175 -1.25 Td
(behavioral and physiological reactivity to pain as a predictor of)Tj
T*
(long-term pain in rheumatoid arthritis patients. Pain )Tj
0 Tc 0 Tw T*
(2001;93:139-46.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875.1 (van Riel PL, Reekers P)110.7 (, van de Putte LB, Gribnau FW)91.7 (. )54.8 (Association)]TJ
2.175 -1.25 Td
[(of HLA)-220.2 (antigens, toxic reactions and therapeutic response to )]TJ
T*
(auranofin and aurothioglucose in patients with rheumatoid arthritis.)Tj
-0.0298 Tw T*
[(T)35 (issue Antigens )-54.8 (1983;22:194-9.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(28.)-875.1 (van de Putte LB, Speerstra F)79.7 (, van Riel PL, Boerbooms )54.8 (AM, van\325)17.7 (t)]TJ
2.175 -1.25 Td
[(Pad Bosch PJ, Reekers P)110.7 (. Remarkably similar response to gold)]TJ
T*
[(therapy in HLA)-220.2 (identical sibs with rheumatoid arthritis. )54.8 (Ann)]TJ
0 Tc T*
(Rheum Dis 1986;45:1004-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(29.)-875.1 (van der Heijde DM, van Riel PL, van Rijswijk MH, van de Putte)]TJ
2.175 -1.25 Td
(LB. Influence of prognostic features on the final outcome in)Tj
T*
[(rheumatoid arthritis: a review of the literature. Semin )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1988;17:284-92.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(30.)-875.1 (V)110.8 (an Riel PL, van de Putte LB, Gribnau FW)91.7 (, de )17.7 (W)79.9 (aal RM. Serum)]TJ
2.175 -1.25 Td
[(IgA)-220.2 (and gold-induced toxic ef)17.7 (fects in patients with rheumatoid)]TJ
T*
[(arthritis. )54.8 (Arch Intern Med 1984;144:1401-3.)]TJ
-2.175 -1.25 Td
[(31.)-875.1 (W)79.9 (elsing PMJ, van Gestel )54.8 (AM, Swinkels HL, Kiemeney LALM, van)]TJ
2.175 -1.25 Td
[(Riel PLCM. )17.7 (The relation between disease activity)64.8 (, joint destruction,)]TJ
T*
(and functional capacity over the course of rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 2001;44:2009-17.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (W)79.9 (elsing PMJ, Landew\216 RBM, van Riel PLCM, et al. )17.7 (The relation)]TJ
2.175 -1.25 Td
(between disease activity and radiological progression in patients)Tj
T*
[(with rheumatoid arthritis. )54.8 (A)-220.1 (longitudinal analysis. \(submitted for)]TJ
0 Tw T*
(publication\).)Tj
0.02499 Tw -2.175 -1.25 Td
[(33.)-875.1 (W)79.9 (elsing PMJ, Severens JL, Hartman M, van Riel PLCM, Laan)]TJ
2.175 -1.25 Td
[(RFJM. Modeling study into the cost-ef)17.7 (fectiveness over 5 years of)]TJ
T*
[(treatment strategies including )17.7 (TNF-blocking treatment and )]TJ
T*
[(leflunomide treatment in )17.7 (The Netherlands. \(submitted for )]TJ
0 Tw T*
(publication\).)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(W)91.9 (elsing and van Riel: Nijmegen inception cohort)]TJ
0 Tc 0 Tw 61.9375 -0.0313 Td
(21)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
79 0 obj
<>stream
8;Z\7$#[X7%+G5@W:(-c,a._`'MSdJ0O"ZSm-:5l\TQf^piEYQ*gbp7nVY;uG^SSs
bTO$XDpQ+3+mhs^AQ5_Gc^.pR2R=%=iUM/%ZGF'3L;g"hYCXKRP`geV8NXgGX\R+q
$Q*I!MMa,JMgQnj"[aDm'Z+"+@'Zts$9>m
?"`Hrr'J:hdm;iT&(9id&7+rt8f9UhaWOnXlI(c3VeCk,Opr@ei^OscH;%d7Vq!Lj
h=I4BC_T%2Y;90Veu=icFk`s)`25XQ4p8oW0f3C%f!tB-gFgF:QG=igf0R;A_b+2r
CZblT8I+P+*63S&Q!O[kD8M-e4QSF=4B@E^'VH0-*qSk(L/QkcBIJFU'2^TAQ$-*G
`H+#YB']#%<;C2XGD*(5SN/`HjD#q]b1r9]R<;*p>b0KPRWO=Q=\DA0Q4:q=&Di>4
EF42m.._4iKl$qJR1S&n8I"j2[UdgJo_,Y7cpXiA\M&tA(sGI,M#,rncYmbsl'RsF
-"q^K)O#bXG>L%R8jZDq`>uudFPQAec/Sf;gI,*%Jm_nt?3S7Q1LuGJ;?!:ld79q]
*!bKlAn3XtF;Fkq&\,*NZ*CR=Z*Eh;@@uQl,8V+;b79"dO'@,2&&j;#cN'`lc,f~>
endstream
endobj
83 0 obj
[/Indexed/DeviceRGB 255 82 0 R]
endobj
82 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
141 0 obj
<>
endobj
104 0 obj
<>
endobj
105 0 obj
<>
endobj
158 0 obj
<>
endobj
194 0 obj
<>
endobj
102 0 obj
<>
endobj
134 0 obj
<>stream
HUiPSY~MH34#hk)*
4DBXBBd B 1
"Ja86펨#*Cv5CUs^25LM:U_:瞯wwqqw>By\$ޑm8R#Ɖ`;FF2'.3fWҩwiG47`²a
#qi=s}v~( <)g?~^p'儈Bn;?=#ƹq8>IIN:WM4d?L 81azL79&KE\.NLJZ~:gd
xqtW[G%
-4,ͰOXاmX,ǶmD ng&*&b`4|Z4݂mz,$f̋/dgX!e[q s6N6\ڑn_[䪭m[;
"0ƿ{CCVnr^9$N(ˑ
cjAVr G+s[ *@)i6]mo|'vNoÛ)鈤-hqrm\vҷ+=sw_=zuS0&wL2Eug7Fr35Aiǂ3$%YM굚Ͱ2l6KK5z,Ҋ&K暔ujSjyR2_82@n@јFv*NVT;K0qZ
+